The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,060
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Severe Mental Illness and Risk of Cardiovascular Disease
Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433
Kimball, A. B., Gladman, D. D., Gelfand, J. M., Gordon, K. B., Horn, E. J., Korman, N. J., Korver, G., Krueger, G. G., Strober, B. E., & Lebwohl, M. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.01.006 · Cited by 431
Martin, S. S., Blaha, M. J., Elshazly, M. B., Brinton, E. A., Toth, P. P., McEvoy, J. W., Joshi, P. H., Kulkarni, K. R., Mize, P. D., Kwiterovich, P. O., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.079 · Cited by 428
Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., SULLIVAN, L. M., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 429
Giugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R. M., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 429
McCrindle, B. W., Urbina, E. M., Dennison, B. A., Jacobson, M. S., Steinberger, J., Rocchini, A. P., Hayman, L. L., & Daniels, S. R. (2007) · Circulation · doi:10.1161/circulationaha.107.181946 · Cited by 418
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410
Self-citationEffects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis
Yamaoka, K., & Tango, T. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-138 · Cited by 409
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 409
Nissen, S. E., Nicholls, S. J., Wolski, K., Rodés‐Cabau, J., Cannon, C. P., Deanfield, J. E., Després, J., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S. R., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1547 · Cited by 407
Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H. G., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192690 · Cited by 410
Epigenetics and cardiovascular disease
Ordovás, J. M., & Smith, C. E. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.104 · Cited by 413
The prevalence, awareness, treatment and control of dyslipidemia among adults in China
Pan, L., Yang, Z., Wu, Y., Yin, R., Liao, Y., Wang, J., Gao, B., & Zhang, L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.006 · Cited by 402
Cannon, C. P., Cariou, B., Blom, D. J., McKenney, J. M., Lorenzato, C., Pordy, R. C., Chaudhari, U., & Colhoun, H. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv028 · Cited by 404
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398
Qaseem, A., Fihn, S. D., Williams, S., Dallas, P., Owens, D. K., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00010 · Cited by 391
Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69292-1 · Cited by 387
Self-citationStramba‐Badiale, M., Fox, K. M., Priori, S. G., Collins, P. D., Daly, C., Graham, I. D., Jonsson, B., Schenck-Gustafsson, K. G., & Tendera, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi819 · Cited by 393
The Perfect Storm of Overutilization
Emanuel, E. J. (2008) · JAMA · doi:10.1001/jama.299.23.2789 · Cited by 390
Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport
Jia, L., Betters, J. L., & Yu, L. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142233 · Cited by 356
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383
Helfand, M., Buckley, D., Freeman, M., Fu, R. F., Rogers, K. R., Fleming, C., & Humphrey, L. L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-7-200910060-00010 · Cited by 383
Sauver, J. L. S., Warner, D. O., Yawn, B. P., Jacobson, D. J., McGree, M. E., Pankratz, J. J., Melton, L. J., Roger, V. L., Ebbert, J. O., & Rocca, W. A. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.08.020 · Cited by 383
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J. B., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., et al. (2009) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m3157 · Cited by 383
Acute Coronary Syndromes: Diagnosis and Management, Part I
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.10.917 · Cited by 390
Athyros, V. G., Doumas, M. N., Imprialos, K. P., Stavropoulos, K., Georgianou, E., Katsimardou, A., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0014-8 · Cited by 384
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Koren, M. J., Scott, R. C., Kim, J. B., Knüsel, B., Liu, T., Lei, L., Bolognese, M. A., & Wasserman, S. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61771-1 · Cited by 366
Ubrogepant for the Treatment of Migraine
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813049 · Cited by 361
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J. Q., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 357
Cardio-Metabolic Benefits of Plant-Based Diets
Kahleová, H., Levin, S., & Barnard, N. D. (2017) · Nutrients · doi:10.3390/nu9080848 · Cited by 383
Current Status of Cardiac Rehabilitation
WENGER, N. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.030 · Cited by 353
A Call to Action: Women and Peripheral Artery Disease
Hirsch, A. T., Allison, M., Gomes, A. S., Corriere, M. A., Duval, S., Ershow, A. G., Hiatt, W. R., Karas, R. H., Lovell, M. B., McDermott, M. M., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31824c39ba · Cited by 358
Shin, J., Lee, J., Lim, S., Ha, H., Kwon, H., Park, Y., Lee, W., Kang, M., Yim, H., Yoon, K., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12075 · Cited by 372
Primary Prevention of Cardiovascular Diseases With Statin Therapy
Thavendiranathan, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2307 · Cited by 349
Weng, T.-C., Yang, Y.-H. K., Lin, S.-J., & Tai, S.-H. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01085.x · Cited by 345
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Self-citationGenetic Testing for Long-QT Syndrome
Kapa, S., Tester, D. J., Salisbury, B. A., Harris‐Kerr, C., Pungliya, M. S., Alders, M. M., Wilde, A. A. M., & Ackerman, M. J. (2009) · Circulation · doi:10.1161/circulationaha.109.863076 · Cited by 345
Statins for Secondary Prevention in Elderly Patients
Afilalo, J., Duque, G., Steele, R. J., Jukema, J. W., de Craen, A. J. M., & Eisenberg, M. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.063 · Cited by 347
Development and validation of a patient self-assessment score for diabetes risk
Bang, H., Edwards, A. M., Bomback, A. S., Ballantyne, C. M., Brillon, D., Callahan, M. A., Teutsch, S. M., Mushlin, A. I., & Kern, L. M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-11-200912010-00005 · Cited by 333
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318212bb8b · Cited by 352
Amarenco, P., Goldstein, L. B., Szarek, M. J., Sillesen, H. H., Rudolph, A. E., Callahan, A. S., III, Hennerici, M. G., Simunovic, L., Zivin, J. A., & Welch, K. M. A. (2007) · Stroke · doi:10.1161/strokeaha.107.493106 · Cited by 342
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Impact of Perinatal Weight Change on Long-Term Obesity and Obesity-Related Illnesses
Rooney, B. L., Schauberger, C. W., & Mathiason, M. A. (2005) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000185480.09068.4a · Cited by 344
Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.064 · Cited by 340
Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H. G., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.010 · Cited by 337
Acute Coronary Syndromes: Diagnosis and Management, Part II
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60674-5 · Cited by 340
Potteaux, S., Gautier, E. L., Hutchison, S. B., van Rooijen, N., Rader, D. J., Thomas, M. J., Sorci‐Thomas, M. G., & Randolph, G. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43802 · Cited by 343
Dhingra, R., & Vasan, R. S. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.11.003 · Cited by 331
Chronic Coronary Artery Disease: Diagnosis and Management
Cassar, A., Holmes, D. R., Rihal, C. S., & Gersh, B. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0391 · Cited by 341
Kolloch, R. E., Legler, U. F., Champion, A., COOPERDEHOFF, R., Handberg, E. M., Zhou, Q., & Pepine, C. J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehn123 · Cited by 330
Sachdeva, A., Cannon, C. P., DEEDWANIA, P. C., LaBresh, K. A., Smith, S. C., Dai, D., Hernandez, A. F., & Fonarow, G. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.08.010 · Cited by 331
Self-citationGrundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Self-citationBiological Activities of Phenolic Compounds of Extra Virgin Olive Oil
Servili, M., Sordini, B., Esposto, S., Urbani, S., Veneziani, G., Maio, I. D., Selvaggini, R., & Taticchi, A. (2013) · Antioxidants · doi:10.3390/antiox3010001 · Cited by 347
Early menopause predicts future coronary heart disease and stroke
Wellons, M., Ouyang, P., Schreiner, P. J., Herrington, D. M., & Vaidya, D. M. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182517bd0 · Cited by 320
Jones, M. L., Martoni, C., Parent, M., & Prakash, S. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511004703 · Cited by 331
Zhao, G., Etherton, T. D., Martin, K. R., Gillies, P. J., West, S. G., & Kris‐Etherton, P. M. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.2.385 · Cited by 324
Vegetarian diets, low-meat diets and health: a review
McEvoy, C. T., Temple, N., & Woodside, J. V. (2012) · Public Health Nutrition · doi:10.1017/s1368980012000936 · Cited by 316
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 324
Effect of Different Antilipidemic Agents and Diets on Mortality
Studer, M., Briel, M., Leimenstoll, B. M., Glass, T. R., & Bucher, H. C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.7.725 · Cited by 317
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30158-5 · Cited by 315
Self-citationDyslipidemia Prevalence, Treatment, and Control in the Multi-Ethnic Study of Atherosclerosis (MESA)
Goff, D. C., Bertoni, A. G., Kramer, H., Bonds, D. E., Blumenthal, R. S., Tsai, M. Y., & Psaty, B. M. (2006) · Circulation · doi:10.1161/circulationaha.105.552737 · Cited by 315
Binder, M. D., van Winkel, R., Eyck, D. V., Hanssens, L., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.12.855 · Cited by 314
Nicotinic Acid: Pharmacological Effects and Mechanisms of Action
Gille, A., Bodor, E. T., Ahmed, K., & Offermanns, S. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094746 · Cited by 316
Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study
Dhamoon, M. S., Sciacca, R. R., Rundek, T., Sacco, R. L., & Elkind, M. S. V. (2006) · Neurology · doi:10.1212/01.wnl.0000201253.93811.f6 · Cited by 307
Statins in the primary prevention of cardiovascular disease
Reiner, Ž. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.80 · Cited by 314
ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting
Bates, E., Babb, J. D., Casey, D. E., Cates, C. U., Duckwiler, G., Feldman, T. E., Gray, W. A., Ouriel, K., Peterson, E. D., Rosenfield, K., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.021 · Cited by 309
McPherson, R., Frohlich, J. J., Fodor, G. J., & Genest, J. J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70310-5 · Cited by 306
Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review
Insull, W. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000208120.73327.db · Cited by 308
Regulation of Intestinal Cholesterol Absorption
Wang, D. Q. ‐. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.160725 · Cited by 311
Lipid Treatment Assessment Project 2
Waters, D. D., Brotons, C., Chiang, C.-W., Ferrières, J., Foody, J. M., Jukema, J. W., Santos, R. D., Verdejo, J., Messig, M., McPherson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.838466 · Cited by 305
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.072 · Cited by 302
Soh, J., Iqbal, J., Queiroz, J., Fernandez-Hernando, C. F., & Hussain, M. M. (2013) · Nature Medicine · doi:10.1038/nm.3200 · Cited by 303
Ray, K. K., Kastelein, J. J. P., Boekholdt, S. M., Nicholls, S. J., Khaw, K., Ballantyne, C. M., Catapano, A. L., Reiner, E., & Lüscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu107 · Cited by 304
de Kreutzenberg, S. V., Ceolotto, G., Papparella, I., Bortoluzzi, A., Semplicini, A., Man, C. D., Cobelli, C., Fadini, G. P., & Avogaro, A. (2010) · Diabetes · doi:10.2337/db09-1187 · Cited by 302
Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status
Won, J. C., Lee, J. H., Kim, J. H., Kang, E. S., Won, K. C., Kim, D. J., & Lee, M. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0017 · Cited by 304
I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica
de Carvalho, M. H. C., Mancini, M. C., de Melo, M. E., Bahia, L., Negrão, C. E., de Matos, L. D. N. J., Sanjuliani, A. F., Kohlmann, O., Oliveira, J. E. P. D., Lerário, A. C., et al. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005000700001 · Cited by 305
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J. T., Musliner, T. A., McCabe, C. H., Veltri, E. P., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 294
Wang, H. H., Garruti, G., Liu, M., Portincasa, P., & Wang, D. Q. ‐. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5495 · Cited by 318
Low CD4+T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study
Lichtenstein, K. A., Armon, C., Buchacz, K. A., Chmiel, J. S., Buckner, K., Tedaldi, E., Wood, K. C., Holmberg, S. D., & Brooks, J. T. (2010) · Clinical Infectious Diseases · doi:10.1086/655144 · Cited by 300
Ezetimibe therapy: mechanism of action and clinical update
Toth, P. P., Phan, B. A. P., & Dayspring, T. D. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 312
Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure
Fukuta, H., Sane, D. C., Brucks, S., & Little, W. C. (2005) · Circulation · doi:10.1161/circulationaha.104.519876 · Cited by 298
Antibiotic Treatment ofChlamydia pneumoniaeafter Acute Coronary Syndrome
Cannon, C. P., Braunwald, E., McCabe, C. H., Grayston, J. T., Muhlestein, B., Giugliano, R. P., Cairns, R., & Skene, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043528 · Cited by 291
Walldius, G., Jungner, I., AASTVEIT, A. H., Holme, I., Furberg, C. D., & Sniderman, A. D. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.254 · Cited by 287
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 308
Extreme lipoprotein(a) levels and improved cardiovascular risk prediction
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.023 · Cited by 284
Song, B., Javitt, N. B., & DeBose‐Boyd, R. A. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.001 · Cited by 295
Liakopoulos, O. J., Choi, Y., Haldenwang, P. L., Strauch, J., Wittwer, T., Dörge, H., Stamm, C., Wassmer, G., & Wahlers, T. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn198 · Cited by 279
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 282
Self-citationNovel Insights into the Pathogenesis and Management of the Metabolic Syndrome
Wang, H. H., Lee, D. K., Liu, M., Portincasa, P., & Wang, D. Q. ‐. (2020) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2020.23.3.189 · Cited by 309
Inflammation, C‐Reactive Protein, and Atherothrombosis
Ridker, P. M., & Silvertown, J. D. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080249 · Cited by 285
The influence of gut microbiota on drug metabolism and toxicity
Li, H., Jiaojiao, H., & Jia, W. P. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 279
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
